Faculty profile

Urban Emmenegger

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Urban Emmenegger

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
44 publications in the last five years, latest in 2026.
Senior (last) author on 12 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

5,300

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Factorial Design Feasibility Geriatric Assessment Geriatric Oncology Hormone Therapies Prostate Cancer Quality Of Life Randomized Controlled Trial

Latest papers

Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature review.
Current opinion in supportive and palliative care · 2026
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.
European urology oncology · 2026
Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel.
Cancer investigation · 2026

All 97 publications

Latest funding

Primary prostate cancer cells as novel models for patient therapy prediction
CIHR · 2023 · Co-investigator
$883,576
Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: the SOAR study
CIHR · 2022 · Co-investigator
$424,576
Comprehensive Health Assessment for My Plan: initial implementation study (CHAMP implementation study)
CIHR · 2022 · Co-investigator
$229,500

All 6 grants and awards

97 publications.

Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature review.

Chen D, Jomy J, Ning T, Cheng S, Khan M, Bottomley A, Cella D, Chung H, Lee SF, Emmenegger U, Hird A, Chow E, Wong HCY, Raman S

Current opinion in supportive and palliative care2026

DOI: 10.1097/spc.0000000000000786 PMID: 41610033

Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.

Armstrong AJ, Saad F, Oya M, Vianna K, Özgüroğlu M, Gedye C, Buchschacher GL, Lee JY, Emmenegger U, Navrátil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Hosius C, McGuinness D, Degboe A, Clarke N

European urology oncology2026

DOI: 10.1016/j.euo.2025.09.010 PMID: 41253648

Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel.

Heo JY, Lee C, Shin H, Cho S, Beom SH, Choi YD, Han WK, Ham WS, Jang WS, Han H, Lee J, Heo JE, Khalaf D, Emmenegger U, Kim S, Kim CG, Jung M, Shin SJ

Cancer investigation2026

DOI: 10.1080/07357907.2026.2672004 PMID: 42138020

STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications.

Heo JY, Sheng M, Khalaf D, Leong HS, Emmenegger U

Prostate cancer and prostatic diseases2026Senior author

DOI: 10.1038/s41391-025-01038-8 PMID: 41131283

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.

Yu EY, Ferrario C, Linch MD, Stoeckle M, Laguerre B, Arranz JA, Todenhöfer T, Fong PC, Piulats JM, Berry W, Emmenegger U, Mourey L, Joshua AM, Mar N, Appleman LJ, Conter HJ, Gravis G, Li XT, Schloss C, Poehlein C, de Bono JS

European urology oncology2025

DOI: 10.1016/j.euo.2024.05.013 PMID: 38926066

Falls in older adults during treatment for metastatic castration-resistant prostate cancer.

Cobbing S, Timilshina N, Tomlinson G, Yang H, Kim VS, Emmenegger U, Alibhai SMH

Journal of geriatric oncology2025

DOI: 10.1016/j.jgo.2024.102047 PMID: 39181835

Decision regret in older men with metastatic castration-resistant prostate cancer and associations with treatment received and baseline variables.

Guo S, Timilshina N, Kim VS, Emmenegger U, Alibhai SMH

Journal of geriatric oncology2025

DOI: 10.1016/j.jgo.2025.102240 PMID: 40288273

Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring.

Gill JK, Sperandio RC, Hoang T, Emmenegger U

The oncologist2025Senior author

DOI: 10.1093/oncolo/oyaf279 PMID: 40973467

Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: The SOAR study protocol.

Jebanesan N, Alibhai SMH, Santa Mina D, Jones J, Legacy N, Freeman L, Smith A, Cobbing S, Vadali N, Lo S, Godhwani K, Nasiri F, Antonio M, Stephens D, Pitters E, Bennie F, Stephens A, Papadakos J, Cerullo L, Zjadewicz M, Jang R, Eng L, Krzyzanowska M, Matthew A, Durbano S, Mehta R, Menjak I, Emmenegger U, Sattar S, Sun V, Ladham K, Puts M

Journal of geriatric oncology2025

DOI: 10.1016/j.jgo.2025.102194 PMID: 39909737

Case Report: Rare meets rare-miliary prostate cancer brain metastasis.

Gill JK, Detsky J, Golan E, Yeung R, Shiner A, Emmenegger U

Frontiers in oncology2025Senior author

DOI: 10.3389/fonc.2025.1649587 PMID: 41341403

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Factorial Design Dear Professor Emmenegger, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature review." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer: a pilot RCT and process evaluation (TOPCOP3)" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Urban Emmenegger

Research

Latest papers

Latest funding

Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature review.

Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.

Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel.

STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications.

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-na&#xef;ve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.

Falls in older adults during treatment for metastatic castration-resistant prostate cancer.

Decision regret in older men with metastatic castration-resistant prostate cancer and associations with treatment received and baseline variables.

Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring.

Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: The SOAR study protocol.

Case Report: Rare meets rare-miliary prostate cancer brain metastasis.

Primary prostate cancer cells as novel models for patient therapy prediction

Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: the SOAR study

Comprehensive Health Assessment for My Plan: initial implementation study (CHAMP implementation study)

TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer: a pilot RCT and process evaluation (TOPCOP3)

Quantifying Osteosarcopenia Progression with Imaging Biomarkers in Prostate Cancer

Feasibility of integrating epigenomic and genomic liquid biopsy biomarkers into the clinical management of advanced prostate cancer

Frequent collaborators

Martine Puts

George Tomlinson

Sebastien Hotte

Hance Clarke

Antonio Finelli

Eitan Amir

Manon Lemonde

Katherine Zukotynski

Eric Winquist

Monika Krzyzanowska

Neil Fleshner

Simon Bergman

Ewa Szumacher

Srikala Sridhar

Christina Canil

Michael Ong

Janet Papadakos

Shabbir Alibhai

Daniel Santa Mina

Mark Clemons

Amy Wong

Andrew Loblaw

Christina Addison

Katherine Zukotynski

Hon Leong

Lawson Eng

Kristen Haase

John Hilton

Honglin Luo

Fei-Fei Liu

Andrea Eisen

Brian Hutton

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.